oral vitamin K antagonists remain the cornerstone of anticoagulation for long-term treatment or secondary prevention. Much of the research in optimizing anticoagulant therapy for acute VTE has ...

Karen L. Hassenplug, Pharm.D.; Jill S. Burkiewicz, Pharm.D., BCPS; Terri L. Jackson, Ph.D., B.S.Pharm.; Laura R. Peppers, Pharm.D., BCPS Identifying baseline ...

Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the route of ...

A recent British study published in European Heart Journal has reignited discussions on the role of sex as a determinant in ...

"Our goal is to provide a safer and superior blood thinner option for patients who rely on chronic anticoagulation but are underserved by current treatments. Warfarin, the first VKA anticoagulant ...

Prescribing anti-clotting medications to adults younger than age 65 who have atrial fibrillation (AFib) but no other risk ...

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...

Prescribing anti-clotting medications to adults younger than age 65 who have atrial fibrillation (AFib) but no other risk ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Nov. 19, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has been ...

The finding throws cold water on the idea that initiating oral anticoagulation (OAC) in younger adults with AF who have no ...